CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

TuHURA Biosciences, Inc./NV

HURA
$133MMicro Cap

Next catalyst

Phase 3March 2027

IFx-Hu2.0

Advanced Or Metastatic Merkel Cell Carcinoma

Get an email about HURA's next catalysts

Track TuHURA Biosciences, Inc./NV (HURA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 3Next

IFx-Hu2.0 Phase 3 Est. Readout

March 2027~IFx-Hu2.0118

Estimated primary completion for IFx-Hu2.0 trial (NCT06947928) in Advanced Or Metastatic Merkel Cell Carcinoma. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaTAMPA19 employees
Drug Pipeline

Frequently asked questions

What is in TuHURA Biosciences, Inc./NV's drug pipeline?β†’

CatalystAlert tracks 1 drug candidate in TuHURA Biosciences, Inc./NV's (HURA) pipeline across Phase 3. Its lead program is IFx-Hu2.0 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is TuHURA Biosciences, Inc./NV's next FDA catalyst?β†’

TuHURA Biosciences, Inc./NV's (HURA) next tracked catalyst is a Phase 3 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track HURA biotech catalysts?β†’

Add HURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TuHURA Biosciences, Inc./NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply